MAIA Biotechnology, Inc.

AMEX:MAIA

Biotechnology

Healthcare
$1.30 +3.41%

+$0.05 today

Market cap
$80.28M
Beta
0.24
P/E (TTM)
-1.8
EPS (TTM)
-$0.76
52W Low $0.87High $3.19

Volume 2.25M

Average 0.78M

MAIA Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

MAIA Biotechnology, Inc.AMEX: MAIA

Operating Expenses · Q1 FY2026 · quarter ended Mar 2026

Operating expenses grows, but more slowly than its trailing trend

Q1 FY2026 operating expenses of $6.95M rose 28.1% year over year, behind the +39.9% change in trailing-twelve-month operating expenses. Sequentially, it rose 61.0% from the prior quarter. Over 3 fiscal years it compounded at +14.5% a year.

Context

  • Operating expenses increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +28.1% toward the trailing-twelve-month pace of +39.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$6.95M+61.0% QoQ
Last fiscal yearDec 2025
$24.27M+43.1% YoY
LTMMar 2026
$25.79M+39.9% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+28.1%——
1 year+43.1%——
3-year CAGR+14.5%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

USD · from the income statement

Latest · FY2025
24.27M USD
Year-over-year change
+43.1%
4-year CAGR
+32.9%

Operating Expenses vs competitors

How MAIA compares with its peers on the latest reported figures

  • MAIA's LTM Mar 2026 operating expenses of $25.79M is the 4th highest of the 7 companies compared; the peer median is $22.33M.
  • Its year-over-year change of +39.9% is the 2nd highest of 7, against a peer median of -8.3%.
  • Over three fiscal years its annual growth of +14.5% compares with a peer median of +6.4%.
MAIA Competitors Peer median
Operating Expenses for MAIA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CELUCelularity Inc.LTM Dec 2025$81.5M +5.0%+50.5%307.0%
ANVSAnnovis Bio, Inc.LTM Mar 2026$41.42M +64.6%+5.2%—
VERUVeru Inc.LTM Mar 2026$28.05M -32.5%-39.9%—
MAIAMAIA Biotechnology, Inc.LTM Mar 2026$25.79M +39.9%+14.5%—
LTRNLantern Pharma Inc.LTM Mar 2026$16.61M -21.7%+7.6%—
PYPDPolyPid Ltd.LTM Mar 2026$16.09M -45.1%-3.9%—
RNXTRenovoRx, Inc.LTM Mar 2026$14.04M +19.5%+10.2%943.0%
Peer median (excluding MAIA) $22.33M-8.3%+6.4%625.0%

Competitors are the stored peer set for MAIA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development3.45M8.93M11.11M10.01M14.55B
Selling, General & Admin4.29M6.14M9.07M6.95M9.72B
Operating Expenses7.79M16.18M20.18M16.96M24.27M
Depreciation & Amortization00000
EBITDA(11.75M)(15.76M)(19.77M)(23.25M)(22.4M)
EBITDA Margin—————
Operating Income(7.79M)(16.18M)(20.18M)(16.96M)(24.27M)
Operating Margin—————
Interest Income2.01K1.87K27.63K318.37K313.95K
Interest Expense827.54K6.97K0570
Other Income / Expenses(4.79M)406.92K409.48K(6.3M)1.87M
Income Before Tax(12.58M)(15.77M)(19.77M)(23.25M)(22.4M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(12.5M)(15.77M)(19.77M)(23.25M)(22.4M)
Net Margin—————
EPS (Basic)(1.18)(1.70)(1.49)(1.05)(0.70)
EPS (Diluted)(1.18)(1.70)(1.49)(1.05)(0.70)
Weighted Avg Shares10.64M9.28M13.26M22.2M32.12M
Weighted Avg Shares (Diluted)10.64M9.28M13.26M22.2M32.12M

MAIA Biotechnology, Inc.

AMEX:MAIA

Intrinsic Alpha fair value

Locked

Current Price

$1.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.